Person: Stone, James
Email Address
AA Acceptance Date
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
First Name
Name
Search Results
Publication Myocardial Infarction Accelerates Atherosclerosis
(Nature Publishing Group, 2012) Leuschner, Florian; Robbins, Clinton; Iwamoto, Yoshiko; Thompson, Brian; Carlson, Alicia L.; Heidt, Timo; Lasitschka, Felix; Etzrodt, Martin; Waterman, Peter; Waring, Michael T.; Chicoine, Adam T.; van der Laan, Anja M.; Niessen, Hans W.M.; Piek, Jan J.; Rubin, Barry B.; Butany, Jagdish; Katus, Hugo A.; Murphy, Sabina A.; Pittet, Mikael; Lin, Charles; Dutta, Partha; Courties, Gabriel; Wei, Ying; Gorbatov, Rostic; Majmudar, Maulik; Stone, James; Morrow, David; Sabatine, Marc; Vinegoni, Claudio; Moskowitz, Michael; Libby, Peter; Swirski, Filip; Weissleder, Ralph; Nahrendorf, MatthiasDuring progression of atherosclerosis, myeloid cells destabilize lipid-rich plaque in the arterial wall and cause its rupture, thus triggering myocardial infarction and stroke. Survivors of acute coronary syndromes have a high risk of recurrent events for unknown reasons. Here we show that the systemic response to ischemic injury aggravates chronic atherosclerosis. After myocardial infarction or stroke, apoE(^{−/−}) mice developed larger atherosclerotic lesions with a more advanced morphology. This disease acceleration persisted over many weeks and was associated with markedly increased monocyte recruitment. When seeking the source of surplus monocytes in plaque, we found that myocardial infarction liberated hematopoietic stem and progenitor cells from bone marrow niches via sympathetic nervous system signaling. The progenitors then seeded the spleen yielding a sustained boost in monocyte production. These observations provide new mechanistic insight into atherogenesis and provide a novel therapeutic opportunity to mitigate disease progression.
Publication Whole-Slide Imaging Digital Pathology as a Platform for Teleconsultation: A Pilot Study Using Paired Subspecialist Correlations
(College of American Pathologists, 2009) Lauwers, Gregory Y.; Wilbur, David; Madi, Kalil; Colvin, Robert; Duncan, Lyn; Faquin, William; Ferry, Judith; Frosch, Matthew; Houser, Stuart L.; Kradin, Richard; Louis, David; Mark, Eugene; Mino-Kenudson, Mari; Misdraji, Joseph; Nielsen, Gunnlauger P.; Pitman, Martha; Rosenberg, Andrew Eric; Smith, R. Neal; Sohani, Aliyah; Stone, James; Tambouret, Rosemary; Wu, Chin-Lee; Young, Robert; Zembowicz, Artur; Wlietmann, WolfgangContext.—Whole-slide imaging technology offers promise for rapid, Internet-based telepathology consultations between institutions. Before implementation, technical issues, pathologist adaptability, and morphologic pitfalls must be well characterized. Objective.—To determine whether interpretation of whole-slide images differed from glass-slide interpretation in difficult surgical pathology cases. Design.—Diagnostically challenging pathology slides from a variety of anatomic sites from an outside laboratory were scanned into whole digital format. Digital and glass slides were independently diagnosed by 2 subspecialty pathologists. Reference, digital, and glass-slide interpretations were compared. Operator comments on technical issues were gathered. Results.—Fifty-three case pairs were analyzed. There was agreement among digital, glass, and reference diagnoses in 45 cases (85%) and between digital and glass diagnoses in 48 (91%) cases. There were 5 digital cases (9%) discordant with both reference and glass diagnoses. Further review of each of these cases indicated an incorrect digital whole-slide interpretation. Neoplastic cases showed better correlation (93%) than did cases of nonneoplastic disease (88%). Comments on discordant cases related to digital whole technology focused on issues such as fine resolution and navigating ability at high magnification. Conclusions.—Overall concordance between digital whole-slide and standard glass-slide interpretations was good at 91%. Adjustments in technology, case selection, and technology familiarization should improve performance, making digital whole-slide review feasible for broader telepathology subspecialty consultation applications.
Publication Mutant Mouse Models Reveal the Relative Roles of E2F1 and E2F3 In Vivo
(American Society for Microbiology, 2002) Cloud, J. E.; Rogers, Catherine; Reza, Tammi; Ziebold, U.; Stone, James; Picard, Michael; Caron, A. M.; Bronson, Roderick; Lees, J. A.The E2F1, -2, and -3 transcription factors are key downstream targets of the retinoblastoma protein (pRB) tumor suppressor that drive expression of proliferation-associated genes. Here we use mutant mouse strains to investigate E2F3's role in vivo. We show that E2F3 is essential for embryonic viability in the pure 129/Sv background but the presence of C57BL/6 alleles yields some adult survivors. Although growth retarded, surviving E2f3−/− animals are initially healthy. However, they die prematurely, exhibiting no obvious tumor phenotype but with the typical signs of congestive heart failure. The defects are completely distinct from those arising in E2f1 mutant mice (S. J. Field et al., Cell 85:549-561; 1996; L. Yamasaki et al., Cell 85:537-548, 1996), supporting the prevailing view that these E2Fs must have some unique biological functions in vivo. To test this model, we examined the phenotypes of E2f1 E2f3 compound mutant mice. Almost all of the developmental and age-related defects arising in the individual E2f1 or E2f3 mice were exacerbated by the mutation of the other E2f. Thus, E2F1 and E2F3 appear to play critical, overlapping roles in the development and maintenance of a variety of tissues. Importantly, this study did identify one major difference in the properties of E2F1 and E2F3: either alone or in combination with E2F1 loss, E2f3 mutation did not increase the incidence of tumor formation. These data strongly suggest that tumor suppression is a specific property of E2F1 and not E2F3.
Publication The infarcted myocardium solicits GM-CSF for the detrimental oversupply of inflammatory leukocytes
(The Rockefeller University Press, 2017) Anzai, Atsushi; Choi, Jennifer; He, Shun; Fenn, Ashley M.; Nairz, Manfred; Rattik, Sara; McAlpine, Cameron; Mindur, John; Chan, Christopher; Iwamoto, Yoshiko; Tricot, Benoit; Wojtkiewicz, Gregory R.; Weissleder, Ralph; Libby, Peter; Nahrendorf, Matthias; Stone, James; Becher, Burkhard; Swirski, FilipMyocardial infarction (MI) elicits massive inflammatory leukocyte recruitment to the heart. Here, we hypothesized that excessive leukocyte invasion leads to heart failure and death during acute myocardial ischemia. We found that shortly and transiently after onset of ischemia, human and mouse cardiac fibroblasts produce granulocyte/macrophage colony-stimulating factor (GM-CSF) that acts locally and distally to generate and recruit inflammatory and proteolytic cells. In the heart, fibroblast-derived GM-CSF alerts its neighboring myeloid cells to attract neutrophils and monocytes. The growth factor also reaches the bone marrow, where it stimulates a distinct myeloid-biased progenitor subset. Consequently, hearts of mice deficient in either GM-CSF or its receptor recruit fewer leukocytes and function relatively well, whereas mice producing GM-CSF can succumb from left ventricular rupture, a complication mitigated by anti–GM-CSF therapy. These results identify GM-CSF as both a key contributor to the pathogenesis of MI and a potential therapeutic target, bolstering the idea that GM-CSF is a major orchestrator of the leukocyte supply chain during inflammation.
Publication Immune Checkpoint Inhibitor Associated Myocarditis Occurs in Both High-Grade and Low-Grade Forms
(Springer Science and Business Media LLC, 2019-09-18) Champion, Samantha; Stone, JamesImmune checkpoint inhibitor (ICI) therapy for malignancy has been associated with adverse events including myocarditis. It has been unclear if there are distinct pathologic grades of ICI associated myocarditis (ICIM) and if such grades are associated with distinct clinical outcomes. Cardiac tissue from 10 patients with ICIM (9 biopsies and 1 autopsy) were evaluated using immunohistochemistry for CD3, CD8, CD68, tryptase, PD-L1 and C4D. The cases were divided into two groups based on the density of CD3+ T cells: high-grade ICIM (H-ICIM, >50 CD3+ cells/hpf) or low-grade ICIM (L-ICIM, ≤50 CD3+ cells/hpf). The densities of macrophages, T cells, eosinophils, necrotic myocytes and PD-L1+ macrophages and myocytes were compared between the two groups and with thirteen cases of grade 2R acute cellular allograft rejection (ACR). Three patients were classified as H-ICIM and seven as L-ICIM. There were higher densities of CD3+ cells and CD8+ cells in H-ICIM and ACR compared with L-ICIM. The number of CD68+ macrophages was higher in H-ICIM compared with L-ICIM and ACR. For both H-ICIM and L-ICIM, there was a higher CD68/CD3 ratio and higher density of PD-L1+ macrophages and myocytes compared with ACR. Clinically, there were trends towards higher serum troponin levels, shorter interval from first ICI treatment, and more frequent female gender in the H-ICIM group compared with the L-ICIM group. All the patients with H-ICIM died, while all the patients with L-ICIM were still living. These data suggest that ICIM occurs in two forms, a high-grade form with increased inflammatory cell infiltration and a more fulminant clinical course, and a low-grade form with a lower degree of inflammatory cell infiltration and a more indolent clinical course. Compared with grade 2R ACR, ICIM is characterized by a more lymphohistiocytic inflammatory infiltrate with an increased CD68/CD3 ratio and increased PD-L1+ macrophages and myocytes.
Publication Consensus Statement on the Pathology of IgG4-Related Disease
(Nature Publishing Group, 2012) Deshpande, Vikram; Zen, Yoh; Chan, John KC; Yi, Eunhee E; Sato, Yasuharu; Yoshino, Tadashi; Klöppel, Günter; Heathcote, J Godfrey; Khosroshahi, Arezou; Ferry, Judith; Aalberse, Rob C; Bloch, Donald; Brugge, William; Bateman, Adrian C; Carruthers, Mollie Nicole; Chari, Suresh T; Cheuk, Wah; Cornell, Lynn D; Fernandez-Del Castillo, Carlos; Forcione, David; Hamilos, Daniel; Kamisawa, Terumi; Kasashima, Satomi; Kawa, Shigeyuki; Kawano, Mitsuhiro; Lauwers, Gregory Y.; Masaki, Yasufumi; Nakanuma, Yasuni; Notohara, Kenji; Okazaki, Kazuichi; Ryu, Ji Kon; Saeki, Takako; Sahani, Dushyant; Smyrk, Thomas C; Stone, James; Takahira, Masayuki; Webster, George J; Yamamoto, Motohisa; Zamboni, Giuseppe; Umehara, Hisanori; Stone, JohnIgG4-related disease is a newly recognized fibro-inflammatory condition characterized by several features: a tendency to form tumefactive lesions in multiple sites; a characteristic histopathological appearance; and—often but not always—elevated serum IgG4 concentrations. An international symposium on IgG4-related disease was held in Boston, MA, on 4–7 October 2011. The organizing committee comprising 35 IgG4-related disease experts from Japan, Korea, Hong Kong, the United Kingdom, Germany, Italy, Holland, Canada, and the United States, including the clinicians, pathologists, radiologists, and basic scientists. This group represents broad subspecialty expertise in pathology, rheumatology, gastroenterology, allergy, immunology, nephrology, pulmonary medicine, oncology, ophthalmology, and surgery. The histopathology of IgG4-related disease was a specific focus of the international symposium. The primary purpose of this statement is to provide practicing pathologists with a set of guidelines for the diagnosis of IgG4-related disease. The diagnosis of IgG4-related disease rests on the combined presence of the characteristic histopathological appearance and increased numbers of IgG4+ plasma cells. The critical histopathological features are a dense lymphoplasmacytic infiltrate, a storiform pattern of fibrosis, and obliterative phlebitis. We propose a terminology scheme for the diagnosis of IgG4-related disease that is based primarily on the morphological appearance on biopsy. Tissue IgG4 counts and IgG4:IgG ratios are secondary in importance. The guidelines proposed in this statement do not supplant careful clinicopathological correlation and sound clinical judgment. As the spectrum of this disease continues to expand, we advocate the use of strict criteria for accepting newly proposed entities or sites as components of the IgG4-related disease spectrum.